Dr. Mona's research interests spans from chemistry and pharmacology to nuclear medicine. Her primary research topic is to evaluate the relevance of stroma-disruption using radionuclide therapy in different cancer paradigms such as pancreatic cancer, prostate cancer and sarcoma as a new therapeutic approach. The investigative strategy is to target stroma/cancer-specific proteins in murine models with radiolabeled ligands and translate the findings to clinical discoveries. Her secondary research topic is to explore rationally chosen, translatable radionuclide therapy-based combination regimens to induce synergistic anti-cancer responses.
K Lückerath, AD Stuparu, L Wei, W Kim, CG Radu, CE Mona, J Calais, M Rettig, RE Reiter, J Czernin, R Slavik, K Herrmann, M Eiber, & WP Fendler. Detection Threshold and Reproducibility of 68Ga-PSMA11 PET/CT in a Mouse Model of Prostate Cancer. J Nucl Med.; 59(9):1392-1397, 2018
K Lückerath, L Wei, WP Fendler, S Evans-Axelsson, AD Stuparu, R Slavik, CE Mona, J Calais, M Rettig, RE Reiter, K Herrmann, CG Radu, J Czernin, & M Eiber. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer. EJNMMI Res.; 8(1):96, 2018
C Meyer, M Dahlbom, T Lindner, S Vauclin, CE Mona, R Slavik, U Haberkorn & J Calais. Radiation dosimetry and biodistribution of 68Ga-FAPi-46 PET imaging in cancer patients. J Nucl Med. 2019 Dec 13: jnumed.119.236786
AD Stuparu, C Meyer, S Evans-Axelsson, K Lückerath, L Wei, W Kim, S Poddar, CE Mona, M Dahlbom, M Girgis, CG Radu, J Czernin, & R Slavik. Targeted alpha therapy in a systemic mouse model of prostate cancer – a feasibility study. Theranostics. 2020; 10(6): 2612–2620
R Brouillette, É Besserer-Offroy, CE Mona, M Chartier, S Lavenus, M Sousbie, K Belleville, JM Longpré, É Marsault, M Grandbois & P Sarret. Cell-penetrating pepducins targeting the neurotensin type 1 relieve pain. Pharmacological research. 2020; 155C:104750